Heads up: this issue is from February 26, 2025. Because it covers time-sensitive coding and regulatory topics, some details may have changed since. See the latest issues for current guidance.
A little history lesson for all of you out there who administer drugs in your office or clinic. In 2006, when all of these admin codes changed from CPT to HCPCS Level II back to CPT, The American Medical Association left the decision about whether or not to consider a drug admin complex up to the Medicare Administrative Contractors. Moreover, when all of this was going on, there were many fewer NON-CHEMO complex drugs. But, over the years, Neurology, Gastro, Allergy, and Dermatology practices have queried how drug admin should be coded for drugs like Ocrevus®, Tysabri™, etc.
In December 2023, CMS directed A/B MACs not to make downward adjustments to claims for CPT Codes for complex therapy administration (96401-96549) based solely on the specific drug being administered. In CMS Technical Direction Letter – Transmittal 12397 (TDL), CMS directed that CPT Codes involving the administration of monoclonal, complex biological, and rheumatological therapies be paid as complex administration as long as all of the elements of these codes that are required for appropriate billing are met.
Flash forward to the Physician Fee Schedule Final Rule. CMS outlined that having every MAC decide for themself was not a good plan. So, they ruled that the CPT® definition should be the standard for billing complex administration codes. To comply with the Final Rule, CMS issued Transmittal 13012. This transmittal basically outlines the CPT guidelines for The Claims Processing Manual, Chapter 12, section 30.5, so now it reads (highlights are mine):
"A/B MACs should consider multiple factors when determining if the level of intensity for a complex drug administration service has been met, rather than just the drug name alone. Chemotherapy administration is considered highly complex and requires a physician or qualified health professional to work and monitor well beyond the level of the therapeutic, prophylactic, and diagnostic injections and infusions code series (96360-96379) due to the high incidence of potentially adverse reactions for the patient. This service typically requires direct supervision from qualified health professionals and/or clinical staff with advanced practice training in the special considerations of preparation, dosage, and disposal, and it often involves frequent monitoring of the patient and conferring with a physician."
Spelling this out for those of you who cannot decipher CMS Manual language, here are the elements that contribute to complex drug administration:
- Drug is riskier than in therapeutic and hydration infusions so they require supervision and monitoring of the infusion;
- Drug may require changes in dosing due to toxicity;
- Drug can cause adverse events, also necessitating monitoring;
- Staff administering has advanced training; and,
- There are special considerations for the preparation, dosing, and disposal of drug(s) administered.
For more information, see Claims Processing Manual, Chapter 12, Section 30.5.
